Da: Marco Saba

A: <stop-u238@i.am> Data invio: sabato 1 gennaio 2000 16.16

Oggetto: Muslim lands to host nuclear waste from the West (Depleted Uranium) > Muslim lands to host nuclear waste from the West (Depleted Uranium) > > Milano, 1 January 2000 - During last years, Iraq, Kuwait, Bosnia and > Kosovo were used by West to discharge almost 500 tons of depleted > uranium, shaped as weapons. Depleted Uranium (DU) is the nuclear waste > coming from the enrichment process of uranium. Many weapons made out of > DU were sold to Saudi Arabia, Egypt, Pakistan (who now has a DU-weapon > factory) and other muslim countries thus increasing the spreading of > this toxic nuclear waste. But now, in US alone, 100,000 soldiers are > suffering from the result of the contamination during the Gulf War. > > In June 1999, in Italy some people created the italian "Committee > against depleted uranium [STOP U-238!] to contrast the spreading of > depleted uranium. The Committee later [13 December 1999] become an > association: "Ethical Environmental Observatory". As a result of the > committee activity, the italian Parliament resolved to create two > inquiry commission on depleted uranium: one national and one european. > Further more, the Parliament resolved to press the US Government to > publish studies about depleted uranium toxicity that are actually keep > secret. > > Depleted uranium is also hidden in many objects that can become in > contact with people: aircraft's, hospitals, helicopters, containers, > etc. > > Aircraft's > > Depleted uranium counterweights may be found in Boeing 747, MDD DC-10, > Hercules C-130, Lockheed 1011 [Tristar], C-141, and Bell helicopters. > In 1992, in Amsterdam, one of the 551 "Boeing 747" built with depleted > uranium counterweights (some 1,500 Kg for each aircraft), crashed > burning in a populated part of the town. DU counterweights are located > in the tail of the 747 where it is also located a secondary fuel tank. > As DU is pyrophoric (i.e. it self-ignite at room temperature), you can > imagine the show! An Hercules C-130 burst in flames 200 mt from Kukes > in Albania the 11 June 1999. Another Boeing 747 (KAL) burst in flames > near London the last 22 December 1999, so many between our readers may > ask themselves: Why insurance from carriers doesn't cover such risks? > > How to treat cancer and leukemia arising from DU contamination? > > Toxicity of DU > > DU has the usual risks of radioactive substances, principally damage > to DNA, which lead to cancer, including leukemia, and hereditary > defects. Given its radioactivity, many US radiobiologists feel that > the risks are small, and that its activity MUST be too low to cause > the reported cancers in Iraqis. On the other hand, there is a growing > body of evidence that the risks of alpha-emitters may be greater than > previously regarded, because of the recently discovered phenomenon of > genomic instability. In the case of DU, if the dust inhaled stays in > the lung, lung cancer is expected. > > Uranium, as a heavy metal, is also chemically toxic, of the same order > as lead and mercury. Ingested oxides could be converted to chlorides > and absorbed. Uranium has been detected in the blood and urine in Gulf > war returnees, apparently in appreciable amounts in the case of some, > including those who went into damaged tanks soon after the war, where > amounts of dust would have been greatest. However, it is difficult to > infer body load of uranium from blood and urine levels. > > The care > > Di Bella's care and cancer prevention may help DU veterans and people > affected by depleted uranium contamination. > > Di Bella is an italian physician working on a mix of retinoids employed > in his therapy against cancer. He start working on this in 40's, he is > now 88. In 1965 Di Bella start experiments with melatonin. In 1974 he > start researching about somatostatin. Ten thousand of italian people > where cared with Di Bella Therapy with great results. We know leukemia > affected people in care since 1974, that are yet alive (1999). > The best results arise when no chemotherapy or radiotherapy was > adopted. Here you can find the base-mix, a list of ingredients, > literature references and other information from the book "Un po' di > verità sulla terapia Di Bella [Some truth from Di Bella's Therapy]- > V. Brancatisano, Travel Factory Srl, December 1999". The work of Di > Bella is today primarily contrasted by De Lorenzo [a former italian > health minister inquired and jailed for corruption] and his fans, i.e. > Dr. Umberto Tirelli who told false data to italian TV and media about > cancer healing. Another contrasting Di Bella's Therapy is Paul Calabresi > from the President (Clinton) Cancer Panel. It seem clear the connection > between the (mis)conduct of WHO [remember the 1959 agreement between > WHO and IAEA to hide adverse radiation effects on human health], the > interests of uranium-corporation and radiotherapy related corporation > in conjunction with pharmaceutical companies. This abnormal connection > find a good ground between physicians oriented by pharmaceutical > companies. > > The Di Bella's therapy has four main counter-indications: > > - it is cheap; > - it does not increase pharmaceutical profits (ascorbic acid, Vitamin > C, cost 16 US$ for a kg. here in Italy, while taxotere (docetaxel), a > dangerous cancer chemoterapic, cost about 16,000,000 US$ for a Kg); > - it is strongly contrasted by "traditional" physicians [some yet > inquired or jailed for corruption]; > - it has not devastating side-effects like radiotherapy or chemotherapy, > so it decrease "business as usual". > > Here is the base-mix that may be adopted for cancer prevention and/or > therapy (posology: follow the doctor's recommendation): > > Acido retinoico (acido all-trans-retinoico, ATRA, tretinoina) [0,5 g] > (to prevent leukemia) > Vitamina A (axeroftolo palmitato) [0,5 g] (to generally prevent cancer) > Provitamina A (beta-carotene) [2 g] (to prevent lung cancer) > Vitamina E (alfa-tocoferolo acetato) [1000 g] (to prevent lung cancer) > > More ingredients can be adopted for cancer therapy on a case-by-case > basis: > > Somatostatina (Etaxene, Ikestatina, Modustatina, Nastoren, Resurmide, > Stilamin, Zecnil) > Bromocriptina (Parlodel) > Octreotide (Sandostatina) > Lisozima > Vitamina B1 (aneurina) > Vitamina B6 > Vitamina C (acido ascorbico, Cebion) > Vitamina D > Melatonina (specifica per le leucemie) > Selenio > Di-idro tachisterolo (A.T. 10) > ACTH, ormone adrenocorticotropo > Oncocarbide > Acidi grassi polinsaturi (PUFA, Poly Unsatured Fatty Acids) > galattosamina > glucosamina > poligalattouronato > > Some components adopted in cancer therapy, but in minimal amount: > Idrossiurea > Ciclofosfamide > > Literature: > > - For Di Bella publications: http://www.tinet.ch/dibella > > (1) Di Bella L., Boll. S.I.B.S., 1940, XV 402 > (2) Di Bella L. "Orientamenti fisiologici nella terapia delle > emopatie", Bull. Med. Sci., Società e Scuola Medica Chirurgica di > Bologna, Anno CXLV-Fasc. I-1974 > (3) Kpthari M., Metha L.A. "Ist Krebs eine Krankheit?", Rowohlt, 1979 > (4) Hudson B.S. & Co. in Lim E. O. "Excited states", 1980, 6, 92-95 > (5) Shekelle R.B. et alia, Lancet, 1981, 2 1185-1190 > (6) "Somatostatin in cancer therapy", 1-3 June 1981 > (7) Russel J. Reiter, The Pineal, Annual Research Reviews, Eden Press, > Volume 6, 1981 > (8) Fukawa K., Nishimura N. et alia "Experimental studies on antitumor > effects of lysozyme", Gan To Kagaku Ryoho 1982; 9(5):915-23 > (9) Lubin B, Machlin LJ "Vitamin E", Ann. NY Acad. Sci. 1982 > (10) Ghirlanda G., Uccioli L., Perri F. "Epidermal Growth factor, > somatostatin and psioriasis", Lancet, i:65-55, 1983 > (11) "Retinoids, differentiation and diseases", Ciba Foundation > Synposia 113, 1985, I-i, London, Pitman > (12) Nomura N.M.Y. Cancer Res. 1985, 45, 2369-72 > (13) Reubi JC "A somatostatin analogue inhibits chondrosarcoma and > insulinoma tumor growth", Acta Endocrinol. 1985; 109:108-114 > (14) Ziegler R.G., Amer. J. Epidemiol. 1986, 123, 1080-1093 > (15) Kvols LK et alia "Treatment of the malignant carcynoid syndrome. > Evaluation of a long acting somatostatin analogue", New England Journal > of Medicine, 1986; 315:663-666 > (16) Kvols LK et alia "Treatment of the malignant carcynoid syndrome > with a long acting somatostatin analogue", Proc AM Soc Clin Oncol 6:95, > 1987 > (17) Lamberts SWJ, Koper JW, Reubi JC "The potential role of > somatostatin analogues in the treatment of cancer", Eur J Clin > Investig. 1987; 18:2188-2194 > (18) Dickson RB, Lippman ME "Estrogenic regulation of growth and > polypeptide growth factor secretion in human breast cancer carcinoma", > Endocrine Rev. 8: 29-43, 1987 > (19) Sainsbury JRC, Farndon JR, Needham GK et alia "Epidermal growth > factor receptor status as predictor of early recurrence and death in > breast cancer", Lancet 1987, i:1398-1402 > (20) Maestroni G., Conti A., Pierpaoli W. "Pineal melatonin, its > fundamental immunoregulatory role in aging and cancer", Ann N.Y. > Acad. Sci. 1988 > (21) Koga M, Eisman JA, Sutherland RL "Regulation of epidermal growth > factor receptor levels by 1,25 dihydroxyvitamin D in human breast > cancer cells", Cancer Res, 48:2734, 1988 > (22) Diplock AT et alia "Vitamin E", Ann. NY Acad. Sci. 1989 > (23) Reichel H, Koeffler HP, Norman AW "The role of the vitamin D > endocrine system on health and disease", N England J of Med, 1989 > (24) Vennin PH, Peyrat JP, Bonneterre J. "Effect of the long acting > somatostatin analogue SMS 201-995 (sandostatin) in advanced breast > cancer", Anticancer Res 9: 153-156, 1989 > (25) Sava G., Benetti A. et alia "Lysozyme and cancer: role of > exogenous lysozyme as anticancer agent", Anticancer Res 1989; > 9(3):583-91 > (26) Sava G., Ceschia V., Pacor S. "Mechanism of the antineoplastic > action of lysozyme: evidence for host mediated effects", Anticancer Res > 1989; 9(4):1175-80 > (27) Stolfi R., Parisi A.M., Natoli C., Iacobelli S. "Advanced breast > cancer: response to somatostatin", Anticancer Res. 10:203, 1990 > (28) Dogliotti L., Berruti A. et alia "Melatonin and human cancer", > J Steroid Biochem Mol Biol, December 20 1990 > (29) Bower M, Colston KW, Stein RC et alia "Topical calcipotriol > treatment in advanced breast cancer", Lancet, 337:701, 1991 > (30) Canobbio L., Baccardo F. et alia "Treatment of advanced pancreatic > carcinoma with the somatostatin analogue BIM 23014. Preliminary results > of a pilot study", Cancer 1992; 69:648-650 > (31) Klijn JGM, Berns PMJJ, Botenbal M. "Clinical breast cancer new > developments in selection and endocrine treatment of patients", > J Steroid Biochem Molec Biol 1992; 43:211-265 > (32) Bendich A. "Biological functions of dietary carotinoids", > Ann. N.Y. Acad. Sci. 1993, 691, 61-67 > (33) Bertram J. S. "Cancer Prevention by Carotinoids" Ann. N.Y. Acad. > Sci. 1993, 691, 177-191 > (34) Canfield L.M. & J.G. Valenzuela, Ann. N.Y. Acad. Sci. 1993, 691, > 192 > (35) Greenberg E.R., Ann. N.Y. Acad. Sci. 1993, 691, 120-126 > (36) Gareval H.S., Ann. N.Y. Acad. Sci. 1993, 691, 139-147 > (37) Serono Symposia USA: "GHRH, GH and IGF-I", Springer Verlag, NY > 1993 > (38) Weckbecker G., Tolcvai L., Stolts B. "Somatostatin octreotide > enhances the antineoplastic effects of tamoxifen and ovariectomy on 7, > 12 DMA induced rat mammary carcinomas", Cancer Res 54; 6334-6337, 1994 > (39) Canobbio L., Cannata D., Miglietta L. "Somatuline (BIM 23014) and > tamoxifen treatment of postmenopausal brest cancer patients: clinical > activity and effect on insulin-like growth factor-I (IGF-I) levels", > Anticancer Res 15: 2687-2690, 1995 > (40) Di Leo A., Bajetta E., Ferrari L. "Biological and clinical > evaluation of Lantreotide (BIM 23014) a somatostatin analogue in the > treatment of advanced breast cancer", Breast Cancer Res Treat > 34:237-244, 1995 > (41) Danesi R., Del Tacca M. "The effects of the somatostatin analog > ocreotide on angiogenesis in vitro", Metabolism 45, 1996, 49-50 > (42) Di Leo A., Bajetta E., Ferrari L. et alia "A dose-finding study > lantreotide (a somatostatin analogue) in patients with colorectal > carcinoma", Cancer 1996, 78:35-42 > (43) Serono Symposia USA: "Growth Hormone Secretagogues", Edd. Barry > B.Bercu & RF Walker, Springer Verlag, NY 1996 > (44) Robbins RJ "Spmatostatin and cancer", Metabolism, 13(8): 98-100 > Aug 1996 > (45) Di Bartolomeo M., Buzzoni R. et alia "Clinical efficacy of > octreotide in the treatment of metastatic neuroendocrin tumors. A study > by the Italian Trials in Medical Oncology Group", Cancer 1996; > 77:402-407 > (46) Klijn JG, Setjono-Ian B et alia "Novel endocrine therapies in > breast cancer", Acta Oncol 1996; 35 Suppl 5:30-7 > (47) Danesi R. et alia "Inhibition of experimental angiogenesis by the > somatostatin analogue octreotide acetate", Clin. Cancer Res., 3(2): > 265-72, Feb. 1997 > (48) Mandelli F. "New strategies for the treatment of acute > promyelocytic", J Intern Med Suppl 1997, 740:23-7 > (49) Panzer A., Viljoen M. "The validity of melatonin as an oncostatic > agent", J Pineal Res, May 1997 > (50) Combs GFJ, Clark LC, Turnbull BW "Reduction of cancer mortality > and incidence by selenium supplementation", Med Klin 1997, > 15 September, 92 Suppl 3:42-5 > (51) Sogounas G, Anagnostou A, Steiner M "DI-alpha-tocopherol induces > apoptosis in erythroleukemia, prostate, amd breast cancer cells", Nutr > Cancer 1997; 28(1): 30-5 > (52) Reynolds C, Montone KT et alia "Expression of prolactin and its > receptor in human breast carcinoma", Endocrinology, Dec 1997; 138(12): > 5555-60 > (53) Lissoni P., Paolorossi F., Tancini G. "A phase II RTOG study in > patients with recurrent malignant astrocytoma", J Neurol. 1998, > 34:193-200 > (54) Brancatisano V. "Di Bella, The man, The cure, a Hope for All", > Ed. Quartet Books, London 1998 > (55) Neri B. et alia "Melatonin as biological response modifier in > cancer patients", Anticancer Research, 18:1329-1332, 1998 > (56) Alaisdair Palmer "Faith, hope and cancer", The Sunday Telegraph, > October 18 1998 > (57) Sheng Y. et alia "DNA repair enhancement by a combined supplement > of carotenoids, nicotinamide, and zinc", Cancer Detect Prev. > 22(4):284-92 1998 > (58) Berghella A.M. et alia "Cancer biotherapy & radiopharmaceuticals", > CNR, l'Aquila - Italia,Vol. 13,4 1998 > (59) Estey EH "New agents for the treatment of acute myelogenous > leukemia: focus on topotecan and retinoids", Leukemia 12 Suppl 1:S13-5, > September 1998 > (60) Satoh K, Ida Y et alia "Induction of apoptosis by cooperative > action of vitamins C and E", Anticancer Res 18(6A):4371-5, Nov-Dec 1998 > (61) Ishihara S, Hassan S et alia "Growth inhibitory effects of > somatostatin on human leukemia cell lines mediated by somatostatin > receptor subtype 1", Peptides 1999; 20(3):313-8 > (62) Reyes J.L. "Compared to what?", BMJ online, January 22 1999 > http://www.bmj.com > (63) Marcus Mullner "Di Bella's therapy: the last word?", British > Medical Journal, January 23 1999, 318:208-209 http://www.bmj.com > (64) Iacona I. et alia "The stability of all-trans retinoic acid in > retinoid solutions of Di Bella's Cure" Dip. di Farmac., IRCCS Policl. > S. Matteo, Pavia, Boll Chim Farm, Jan 1999, 138:1, 1-6 > (65) Marcus Mullner, Stephen JW Evans, British Medical Journal 1999, > 318:1073 http://www.bmj.com > (66) Hayes A.J., L Y Li, M E Lippman "Science, medicine and the future > - Antivascular therapy: a new approach to cancer treatment", British > Medical Journal, March 1999, Vol.318 p.855 > (67) O'Byrne et alia "Phase II study of RC-160 (vapreotide), an > octapeptide analogue of somatostatin, in the treatment of metastatic > breast cancer", Br J Cancer, 79(9-10):1413-8, March 1999 > (68) Lissoni P, Tancini G, Paolorossi F et alia "Chemoneuroendocrine > therapy of metastatic breast cancer with persistent thrombocytopenia > with weekly low-dose epirubicin plus melatonin: a phase II study", > J Pineal Res 1999 April; 26 (3): 169-73 > (69) Sheu JR et alia "Comparison of the relative activities of > alpha-tocopherol and PMC on platelet aggregation and antioxydative > activity", Life Sci 1999; 65(2): 197-206 > (70) Albini A. et alia "Somatostatin controls Kaposi's sarcoma tumor > growth through inhibition of angiogenesis", INRC, Genova, April 1999 > (71) "Vitamin E May Prove to Be A Weapon Against Lung Cancer", Cancer, > November 1999, > http://www2.cancer.org/zine/crc_news.cfm?story=001_11161999_0&ct=1 > > To get the Di Bella's Therapy in Italy, you can contact: > AIAN, Associazione Italiana Ammalati Neoplastici, > via Magna Grecia 39 - Roma - Italy > http://www.aian.org > ---------------------------------------------- > Do you want to help the italian Committee to stop the spreading of > depleted uranium? Do you want to help us to take care of people with > Di Bella's therapy? > > Contact: > Marco Saba > marcosaba@xoommail.com > O/E/A - Osservatorio Etico Ambientale > Comitato "STOP U-238!" > via F.lli Cervi Res. Idra > 20090 Segrate (MI) - Italy > Phone: (Italy+) 2 21591373 > http://stop-u238.i.am >